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The intracellular transport of cholesterol is subject to tight regulation. The structure of the
lysosomal integral membrane protein type 2 (LIMP-2, also known as SCARB2) reveals a large
cavity that traverses the molecule and resembles the cavity in SR-B1 that mediates lipid
transfer. The detection of cholesterol within the LIMP-2 structure and the formation of
cholesterol−like inclusions in LIMP-2 knockout mice suggested the possibility that LIMP2
transports cholesterol in lysosomes. We present results of molecular modeling, crosslinking
studies, microscale thermophoresis and cell-based assays that support a role of LIMP-2 in
cholesterol transport. We show that the cavity in the luminal domain of LIMP-2 can bind and
deliver exogenous cholesterol to the lysosomal membrane and later to lipid droplets.
Depletion of LIMP-2 alters SREBP-2-mediated cholesterol regulation, as well as LDL-receptor
levels. Our data indicate that LIMP-2 operates in parallel with Niemann Pick (NPC)-proteins,
mediating a slower mode of lysosomal cholesterol export.
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Cholesterol dictates the biophysical properties of mamma-lian membranes and is involved in the pathophysiology ofvarious diseases1. Its transport and subcellular distribution
are subject to tight regulation2–4. Cholesterol is an important
membrane component of higher eukaryotes, regulating barrier
function, membrane ﬂuidity, integral membrane protein opera-
tion, membrane trafﬁc and transmembrane signaling processes4. It
also plays a major role in vascular diseases, diabetes, cancer and
several monogenic disorders5. Cholesterol delivery to cells by low-
density lipoprotein (LDL) requires endocytosis of the LDL-LDL
receptor (LDLR) complex. After reaching late endosomes/lyso-
somes the cholesteryl esters are hydrolyzed by acid lipase. Because
the level of cholesterol in the limiting membrane of lysosomes6 is
rather low, a transport process across this membrane followed by
delivery to another membrane is thought to exist. Export of
cholesterol from lysosomes has been mainly linked to Niemann
Pick Type C1 and 2 proteins7. Two proteins NPC1 and NPC2,
both equipped with sterol-binding domains, cooperate to remove
cholesterol from lysosomes8. NPC2 is envisaged to bind choles-
terol in the lumen and to directly transfer it to NPC1. NPC1 is
then thought to transport cholesterol into and/or across the
lysosomal membrane. How cholesterol is subsequently delivered
to other membranes, such as the ER, endosomes, mitochondria
and the plasma membrane is still largely unknown. One of the
most abundant membrane proteins of the lysosome, the
lysosomal-associated membrane protein LAMP-2, was suggested
to accept cholesterol from NPC2, thereby contributing to the
NPC1-driven cholesterol efﬂux from lysosomes9,10.
Another abundant and central lysosomal membrane component
is LIMP-2. LIMP-2 is the only endomembrane member of the
CD36 superfamily of scavenger receptors, which also include the
plasmalemmal SR-BI and CD36. The receptors are characterized by
two transmembrane domains11, short cytosolic tails and a large
ectodomain. LIMP-2 functions as a phospholipid receptor12, and as
a receptor for enterovirus 71 and coxsackieviruses13.
LIMP2 is known to deliver the acid hydrolase β-glucocerebrosidase
to lysosomes14; β-glucocerebrosidase binding is mediated by a helical
loop localized in the apex of the luminal domain of LIMP-215,16 that
extends beyond the glycocalyx. Remarkably, unlike other chaperones
that cycle between the Golgi and lysosomes, LIMP-2 resides largely in
the lysosomes, suggesting that it serves a second, heretofore unknown
function. Accordingly, in addition to the apical helical loop, the
LIMP-2 ectodomain features a sizeable cavity that could conceivably
mediate an additional, likely transport-related function. Notably, the
other members of this family—SR-B1 and CD36, which are
expressed on the cell surface—mediate the uptake of fatty acids and
lipoprotein-associated lipids. Like LIMP-2, the ectodomain of SR-B1
displays an intramolecular tunnel that is thought to deliver choles-
terol from bound lipoproteins to the plasma membrane15. A similar
cavity in the ectodomain of CD36 has been implicated in steroid
delivery in Drosophila17. That the LIMP-2 ectodomain may play a
similar role is suggested by the recent detection of a cholesterol
molecule buried inside the hydrophobic tunnel of the puriﬁed,
crystalline protein12.
In this study, we provide multiple lines of evidence that LIMP-
2 participates in lipid transport from lysosomes by transporting
cholesterol (and possibly also other lipid species) through its
luminal cavity to the lysosomal membrane.
Results
Interaction of LIMP-2 and cholesterol. It is striking that in
LIMP-2-deﬁcient mice, which are characterized by ureter
pathology, deafness and peripheral neuropathy18, we observed
intracellular structures resembling cholesterol crystals. Such
cholesterol-like inclusions are especially prominent in cell bodies
of Schwann cells of peripheral nerves of LIMP-2 knockout mice
(Fig. 1a). Similar structures were previously described in macro-
phages residing in atherosclerotic lesions19. Prompted by the
presence of a cavity in the extracellular domain of LIMP-212, we
performed unrestrained molecular dynamic simulations (MDS)
to examine whether and where cholesterol binds preferentially
within the putative uptake pathway (the tunnel). Twenty-four
simulations were initiated with cholesterol in the bulk solution
and ﬁfteen with cholesterol docked within the LIMP-2 cavity. A
spatial distribution function of cholesterol computed using the
combined dataset depicts cholesterol-binding positions from the
mouth of the putative uptake pathway to the membrane interface,
as well as the helical bundle face (Fig. 1b). The amino acids
residues V214, V268, V277, M337, F339, I376, A379, K381, V415
were found to be lining the cholesterol-binding site within the
tunnel of the LIMP-2 ectodomain.
To validate the association of LIMP-2 with cholesterol (and/or
other lipids) we examined the interaction of recombinant LIMP-2
ectodomain with lipids using UV-crosslinkable bifunctional
derivatives, as well as microscale thermophoresis. Trans-sterol
bound readily to LIMP-2, while fatty acids, ceramide and
sphingosine bound with lower afﬁnity (Fig. 1c and Supplemen-
tary Fig. 1A). In addition, using microscale thermophoresis20 we
detected a direct interaction between puriﬁed, soluble His-tagged
LIMP-2 protein labeled with Red-tris-NTA dye and cholesterol
(Supplementary Fig. 1B; EC50= 112 ± 32 nM).
We next investigated whether LIMP-2 deﬁciency affects the
lysosomal clearance of cholesterol from exogenously added low-
density lipoprotein (LDL). To this end, control and LIMP-2-
deﬁcient mouse embryonic ﬁbroblasts (MEFs) were starved of
lipoproteins for 16 h and subsequently exposed to LDL-
cholesterol for 6 h. Lysosomal cholesterol was visualized using
ﬁlipin, a polyene macrolide antibiotic that selectively binds to
unesteriﬁed cholesterol. Signiﬁcantly more cholesterol-containing
vesicles were observed in cells lacking LIMP-2, suggesting the
involvement of LIMP-2 in lysosomal cholesterol efﬂux (Fig. 1d,
e). Neither LIMP-2 overexpression (Supplementary Fig. 1C) nor
its depletion (Supplementary Fig. 1D, Fig. 4a) altered the stability
of NPC1. Furthermore, the ﬁlipin-positive vesicles are likely to be
NPC1-positive, given the co-localization of LIMP-2 with NPC1 or
with the lysosomal marker LAMP-2 (Supplementary Fig. 1E).
Taken together these ﬁndings suggest that LIMP-2 deﬁciency in
MEFs promotes a lysosomal cholesterol accumulation despite the
presence of NPC1.
To validate the ability of LIMP-2 to bind and possibly
transport cholesterol we made use of NPC1-deﬁcient CHO-
M12 cells21. Loss of NPC1 in these cells leads to a characteristic
intralysosomal cholesterol accumulation, as visualized by ﬁlipin
staining22. Importantly, overexpression of murine LIMP-2 in
NPC1-deﬁcient cells reduced the cholesterol load, speciﬁcally in
those vesicles where the mCherry-tagged LIMP-2 was present
(Fig. 1f, g). Together, these in vitro and in vivo experiments
suggest a role of LIMP-2 in cholesterol transport.
Cholesterol translocates through the LIMP-2 ectodomain. To
more readily analyze the mechanism underlying LIMP-2-
mediated cholesterol translocation out of the lysosomal lumen,
we generated an engineered LIMP-2 construct that was targeted
to the plasma membrane. To this end, we created a chimera
where the cytoplasmic C-terminal domain of LIMP-2 (aa
457–478) was substituted by that of CD36 (aa 463–472) (Sup-
plementary Fig. 2A; hereafter denoted as LIMP-2.cmr), a related
scavenger receptor expressed constitutively at the plasma mem-
brane. Visualization was facilitated by tagging the chimera with
GFP. We initially veriﬁed that the resulting LIMP-2 chimeric
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construct was in fact expressed at the plasma membrane. Unlike
the full-length wildtype LIMP-2, which is found almost entirely in
late endocytic compartments where it colocalizes with inter-
nalized dextran, the chimera is clearly discernible at the plasma
membrane (Fig. 2a). Exposure of the chimera (but not of full-
length LIMP-2) to the extracellular milieu was validated using
impermeable biotin derivatives (Fig. 2b).
We proceeded to test the ability of the plasmalemmal LIMP-2.
cmr to transport cholesterol. This required a delivery vehicle that
would bind to the extracellular (normally luminal) domain of
LIMP-2. Given its structural similarity to CD36 and SR-B1, which
are known to bind ApoB- and ApoA1-containing lipoproteins, we
tested whether the exofacial domain of LIMP-2 would similarly
bind these lipoproteins. As shown in Fig. 2c, d, DiI-labeled LDL
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bound to cells expressing LIMP-2.cmr, but not full-length LIMP-
2 (Supplementary Fig. 2B). Similar results were obtained when
recombinant LIMP-2 ectodomain tethered on liposomes was
tested (Supplementary Fig. 2C). Remarkably, LDL bound to
LIMP-2 only at acidic pH, akin to the lysosomal pH that LIMP-2
is normally exposed to (Fig. 2c, d). Like LDL, DiI-labeled HDL
also bound to cells expressing LIMP-2.cmr only at acidic pH
(Supplementary Fig. 2D). Having identiﬁed a suitable delivery
vehicle, we tested whether the chimera functioned to deliver
cholesterol to the membrane. LDL was chosen as a vehicle
because this lipoprotein is internalized and delivered to late
endosomes/lysosomes, where LIMP-2 resides. The lipoprotein
was doubly labeled with Alexa Fluor 647 succinimidyl ester (to
tag the apoprotein) and BODIPY cholesterol (BC; a ﬂuorescent
cholesterol analog), and is hereafter denoted as AF647-LDL(BC).
After a short incubation with AF647-LDL(BC), CHO and HeLa
cells expressing LIMP-2.cmr (tagged with mCherry) displayed
ﬂuorescent cholesterol analog in their plasma membrane.
Washing the cells repeatedly with HBSS removed the apoprotein,
yet ﬂuorescent cholesterol remained associated with the mem-
brane, implying that cholesterol had been delivered from LDL to
the plasmalemma (Fig. 2e, Supplementary Fig. 2E). Importantly,
we also recapitulated the LIMP-2-mediated transport of LDL-
derived cholesterol using recombinant LIMP-2 ectodomain
tethered on liposomes (Supplementary Fig. 2F).
Next, we investigated whether the tunnel in the core of the
exofacial domain of LIMP-2 is involved in lipid translocation
(Fig. 1b). To this end, we mutated amino acids lining the tunnel
to bulkier residues (A379W/V415W; Fig. 2f), expected to obstruct
lipid translocation. The A379W/V415W double mutation had
little effect on the plasmalemmal localization of the chimera
(Supplementary Fig. 2G) or on AF647-LDL binding (Supple-
mentary Figs. 2H, I), but signiﬁcantly reduced its ability to
transfer ﬂuorescent cholesterol both in HeLa and CHO cells
(Fig. 2g, h and Supplementary Fig. 2J).
To further investigate if the LIMP-2 cholesterol transport
activity is restricted to lipoproteins like LDL, we examined
whether other types of lipoproteins could deliver cholesterol
to LIMP-2. Recently, saposin A (SapA)—a member of the
lysosomal saposin family required for the lysosomal break-
down of certain lipids—was shown to form picodiscs with
lipids in a manner similar to that of HDL23. Like LDL and
HDL, SapA-containing lipoproteins not only bound to LIMP-
2 but delivered cholesterol to cells in a manner that depended
on the integrity of the LIMP-2 tunnel function (Fig. 2i,
Supplementary Fig. 2K). Hence, the luminal domain of LIMP-
2, and likely its tunnel structure, are critical to deliver
lipoprotein-associated cholesterol (and conceivably other
lipids) to the membrane.
Cholesterol delivery to lipid droplets mediated by LIMP-2.
Having demonstrated that its luminal domain is able to transfer
cholesterol from the extracellular milieu to the plasma membrane
in a tunnel-dependent manner, we turned to in situ (cell-based)
assays to assess whether LIMP-2 can similarly transport choles-
terol from the lysosomal lumen, to be delivered ultimately to lipid
droplets, the storage sites of esteriﬁed cholesterol24. To follow this
pathway in the presence or absence of LIMP-2, human epithelial
cells (A431) were labeled for 24 h with oleic acid-conjugated BSA
to generate lipid droplets (LD)25,26. Cells were subsequently
labeled for 2 h with BODIPY cholesteryl linoleate-labeled LDL
(BC LN-LDL) that enters late endosomes27, and chased for up to
4 h in serum-free medium to monitor the transfer of BODIPY
cholesterol (BC) from late endosomes to LD (Fig. 3a). BODIPY
cholesterol (BC) is the product of BODIPY cholesteryl linoleate
(BC LN) hydrolysis by lysosomal acid lipase. The acidic hydro-
lysis of BC LN is known to be slower than that of native CEs;
however this apparent disadvantage makes it a suitable tool to
monitor defects in lysosomal cholesterol export by ﬂuorescence
microscopy27. To determine the role of LIMP-2 in transport
across the membrane, cells were treated either with control,
NPC1 or LIMP-2 siRNAs (Fig. 3b, c). In control siRNA-treated
cells, a considerable fraction of the labeled cholesterol was loca-
lized to LD after 4 h, whereas the knockdown of NPC1 resulted in
the accumulation of cholesterol in late endosomes, with only
minute levels found in LD. Importantly, the downregulation of
LIMP-2 also led to an increase in the fraction of BODIPY cho-
lesterol found in late endosomes (Fig. 3b, c). We also used siRNA
to compare the contribution of LIMP-2 to that of NPC1. The
effect of LIMP-2 silencing was less pronounced than the one of
NPC1. The inhibition caused by LIMP-2 knockdown could be
prevented by re-expression of murine mCherry tagged LIMP-2,
leading to a redistribution of cholesterol similar to that of control
siRNA-treated cells (Fig. 3b, c). Importantly, a murine LIMP-2
double mutant (G379W/V415W) corresponding to the human
mutations (A379W/V415W) within the tunnel domain described
above14, was less effective in facilitating cholesterol delivery to
LD, suggesting a direct involvement of LIMP-2 in this transport
process (Fig. 3b, c and Supplementary Fig. 3A). The same tunnel
mutant was used to transfect NPC1-deﬁcient CHO M12 cells. In
contrast to the transfection with wildtype LIMP-2 (Fig. 1f), the
tunnel mutant failed to reduce the vesicular ﬁlipin accumulation
(Fig. 3d, Fig. 1g).
To gain further insight into the fate of cholesterol, LIMP-2
wildtype and deﬁcient mouse embryonic ﬁbroblasts (MEFs) were
incubated with [3H]cholesterol-labeled LDL and the incorpora-
tion of the radiolabel into cholesteryl esters (CE) was determined.
Thin-layer chromatography (TLC) revealed that the amount of
[3H]CE after a 5 h chase was strongly reduced in LIMP-2
Fig. 1 Physical and functional interaction between LIMP-2 and cholesterol. a Electron microscopy revealed characteristic membrane-surrounded
cholesterol-like inclusion bodies within the cytoplasm of Schwann cells of the Nervus phrenicus of a 6.5 month old (upper panel) and N. ichiadicus of a
6.5 month and 23 month old (lower panel) LIMP-2-deﬁcient mouse. Scale bars: (upper panel left, lower panel right) 250 nm (upper panel right) 500 nm,
(lower panel left) 1000 nm. b Spatial distribution function of cholesterol (orange) in the LIMP-2 extracellular domain (tan) computed from MDS, shown as
a cross-section through an axial slice (lighter orange) of the structure. c Trans-sterol can be UV-crosslinked to the recombinant ectodomain (luminal part
of LIMP-2 (aa35− aa430); +) whereas without the lipid (negative control; −) no crosslinking was observed. The lower panel shows the LIMP-2 protein
after Coomassie staining. d Wildtype (WT) and LIMP-2-deﬁcient (KO) mouse embryonic ﬁbroblasts (MEFs) were grown for 16 h in lipoprotein-deﬁcient
medium and subsequently challenged for 6 h with LDL. Intracellular cholesterol was visualized with ﬁlipin. Lysosomes were stained with LIMP-2 in WTMEF
cells. Scale bar: 10 μm. e Quantiﬁcation of cellular ﬁlipin intensity from D (mean ± SD; LIMP-2-WT n= 25, LIMP-2-KO n= 22 cells from one experiment;
****P < 0.0001, t-test). f Wide-ﬁeld ﬂuorescence micrographs of ﬁlipin-stained NPC1-deﬁcient CHO M12 cells overexpressing LIMP-2-WT-mCherry.
Arrowheads indicate examples of ﬁlipin-positive LIMP-2-containing LEs. Note the decrease of ﬁlipin ﬂuorescence in LIMP-2-WT-mCherry-containing LEs.
Scale bar, 10 μm. g Quantiﬁcation of mean ﬁlipin intensity in wild type (WT.mCherry), tunnel-blocking mutant form of LIMP-2 (G379W/V415W.mCherrry)
and non-expressing (LIMP-2 neg.) LEs (n= 75, 77, 152 organelles, respectively, from in 15 cells). Data (mean ± SEM) from two independent experiments,
unpaired two-tailed Student’s t-test (****P < 0.0001). Source data are provided as a Source Data ﬁle
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knockout compared to wildtype MEFs (Fig. 3e), in agreement
with the imaging results (Fig. 3b, c). Similar results were obtained
when cells were radiolabeled with [3H]oleic acid:BSA complex
with or without simultaneous addition of LDL, followed by
determination of the incorporation of [3H]oleate into CE
(Supplementary Fig. 3B, C). Of note, although the concurrent
addition of LDL led to an overall increase in [3H]CE, as expected,
the difference between wildtype and LIMP-2 knockout cells was
maintained in the absence of LDL (Supplementary Fig. 3C). This
further suggests that the cholesterol esteriﬁed is not derived solely
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from exogenous sources (i.e., LDL). In both labeling experiments,
cells treated with the ACAT inhibitor PKF or with the inhibitor of
lysosomal cholesterol efﬂux U18666A, displayed essentially no
radiolabeled CE (Fig. 3e, Supplementary Fig. 3C). These dynamic
cell-based experiments underline a physiologically relevant role of
LIMP-2 in mediating cholesterol export from lysosomes.
LIMP-2 is involved in regulating cholesterol homeostasis. Due
to the central role of cholesterol in metabolism, its cellular
homeostasis is tightly regulated1. Changes in intracellular cho-
lesterol levels are sensed in the endoplasmic reticulum (ER) and
cause adaptations in proteins involved in cholesterol synthesis
and uptake1. Upon cholesterol depletion, a nuclear fragment of
the transcription factor sterol regulatory element binding protein
2 (SREBP2) is generated and activates the transcription of sterol-
responsive genes like LDLR and HMG-CoA reductase1,28. When
lysosomal cholesterol egress is hampered, as in the case of NPC1-
deﬁciency, signaling by the nuclear SREBP2 is constitutively
active, despite sufﬁcient extracellular supply of cholesterol29
(Supplementary Fig. 4A). We speculated that depletion of LIMP-2
would result in an altered response of ER-resident regulators of
cholesterol homeostasis. To test this possibility, we assessed the
effect of depletion or replenishment of cholesterol on the nuclear
formation of SREBP2 in the presence or absence of LIMP-2 or
NPC1. HeLa cells were treated with control, NPC1 or LIMP-2
siRNAs, followed by 14 h incubation in full medium, cholesterol-
depleted medium, or cholesterol-depleted medium with an
additional 6 h of re-addition of LDL (Fig. 4a). While re-addition
of LDL led to a prominent decrease of nSREBP2 in control cells,
no decrease was noted in NPC1 depleted cells. LIMP-2 depletion
had a similar, though less drastic effect (Fig. 4a, b). To understand
the kinetics of nSREBP2 generation caused by delivery of LDL-
derived cholesterol from the lysosome to the ER, we also explored
shorter periods (2 and 3 h) of LDL-re-addition (Supplementary
Fig. 4, B, C, D). We observed that the knockdown of LIMP-2
delayed the termination of the nSREBP2 signal (Supplementary
Fig. 4B). In line with these ﬁndings, the expression of the
downstream target of nSREBP2, the LDL receptor (LDLR), was
increased in the LIMP-2 knockdown cells despite LDL addition.
Even though LDL re-addition did not change the level of
nSREBP2 in NPC1 deﬁcient cells by 10 h, after 24 h the levels of
nSREBP2 were clearly decreased (Fig. 4c, Supplementary Fig. 4E,
4F). This could suggest alternative, though slower export routes of
cholesterol from lysosomes, e.g., via LIMP-2. Indeed, the parallel
depletion of NPC1 and LIMP-2 in HeLa cells caused an accu-
mulation of nSREBP2 after 24 h of LDL re-addition (Fig. 4c, d).
This effect was even more pronounced when LDLR levels were
monitored, i.e., a decreased level of LDLR in NPC1 knockout
cells, but no change in LIMP-2/NPC1 double-deﬁcient cells
(Fig. 4c, e, Supplementary Fig. 4E–F). An additional downstream
target of nSREBP2, 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase (HMGCR), was affected in a similar manner, leading to
higher protein levels of HMGCR after re-addition of LDL for 24 h
in NPC1/LIMP-2 double-depleted cells than in the cells lacking
only NPC1 (Supplementary Fig. 4F, G).
Discussion
Unwarranted lipid accumulation in the lysosomes is a hallmark of
lipidoses, which can lead to a number of lysosomal storage dis-
orders such as Niemann-Pick disease, Sandhoff disease, Tay-
Sachs disease, Farber disease, and Gaucher’s disease, depending
on the type of accumulated lipid30. Whereas the endolysosomal
enzymes and nonenzymatic proteins involved in late endosomal/
lysosomal lipid metabolism (e.g., the sphingolipid activator pro-
teins (SAPs)) are rather well characterized, not much is known
about presumptive late endosome/lysosome lipid transporters,
other than NPC1 and LAPTM4B31. Although NPC1 poly-
morphisms were shown to lead to a lysosomal cholesterol accu-
mulation, the lifespan of patients bearing these mutations varied
with the age of onset. This, we believe, points to other pathway(s)
of lysosomal cholesterol recycling that work in parallel with the
NPC1 pathway. These alternate pathways can seemingly trans-
port cholesterol with different kinetics and efﬁcacies, which may
also depend on the cell type or total levels of incoming
lipoprotein-derived cholesterol.
Herein, we present evidence that LIMP-2 contributes to the
recycling of lysosomal LDL-derived cholesterol (and possibly
other lipids) alongside the NPC1 pathway. This conclusion is
supported by a number of lines of direct experimental (as well as
circumstantial) evidence. We demonstrate that LIMP-2 directly
interacts with cholesterol and can transport lipoprotein-derived
cholesterol or cholesterol analogs to limiting membranes via the
LIMP-2 ectodomain tunnel. In addition, knock-down experi-
ments showed that LIMP-2 depletion leads to upregulation not
only of cholesterol biosynthesis but also of LDLR expression. Of
note, co-precipitation experiments (Supplementary Fig. 4H) did
not reveal endogenous interaction of LIMP-2 with NPC1 or
Fig. 2 Lipoprotein-derived cholesterol can translocate through the LIMP-2 ectodomain. a Confocal microscopy of HeLa cells transiently expressing C-
terminally GFP-tagged wild-type (WT.GFP) or chimeric LIMP-2 (cmr.GFP). Cells were labeled with dextran to visualize late endosomal organelles. Cell
boundaries are indicated by dotted lines. b Plasmalemmal expression of chimeric C-terminally GFP-tagged LIMP-2 (LIMP-2.cmr.GFP) in CHO cells was
detected using Western blotting of biotinylated cell surface proteins after immunoprecipitation using streptavidin-beads. LIMP-2.GFP was used as a
negative control. β-actin was used as a loading control for the input samples. c Confocal microscopy and quantiﬁcation (d) of DiI-LDL binding to LIMP-2.
cmr.GFP in CHO cells. Cells transiently expressing LIMP-2.cmr.GFP were incubated with DiI-LDL at pH 5 (upper panel) and pH 7 (lower panel). pH 5: n=
78, pH 7: n= 9 cells from two experiments. t-test (****P < 0.0001). e Confocal microscopy of CHO cells transiently expressing LIMP-2.cmr.mCherry and
incubated with doubly labeled LDL, AF647-LDL(BC), after binding (upper panel) and washing with HBSS (lower panel). Note that AF647 was removed
upon washing but BC was not. f Representation of the tunnel-blocking mutations of the human LIMP-2 luminal tunnel, shown as a slice through the body of
the protein (sliced solid shown in orange). Residues A379 and V415, which point towards the cavity of the tunnel, are shown in blue. g, h Confocal
microscopy (g) and quantiﬁcation (h) of AF647-LDL(BC)-derived BC transport in CHO cells expressing LIMP-2.cmr.mCherry or LIMP-2.cmr.A379W/
V415W.mCherrry proteins. Cells were pre-incubated with doubly labeled LDL (AF647-LDL(BC)) and washed with HBSS. The ratio of green (BC) over far-
red (AF647-labeled LDL) ﬂuorescence, measured in ZEN Lite (Zeiss), was used to estimate uptake (h); LIMP-2.cmr.mCherry n= 59, LIMP-2.cmr.A379W/
V415W.mCherrry n= 50 cells from 3 experiments). i Quantiﬁcation of BC uptake from SapA(BC) by CHO cells transiently expressing C-terminally
mCherry-tagged-wild type (LIMP-2.cmr.mCherry) or tunnel-blocking mutant LIMP-2 chimera (LIMP-2.cmr.A379W/V415W.mCherrry). Also presented is
the total ﬂuorescence intensity of non-transfected cells. The total cellular ﬂuorescence intensity of BC was measured using Volocity (LIMP-2.cmr.mCherry
n= 67, LIMP-2.cmr.A379W/V415W.mCherrry n= 90, non-transfected cells n= 152 cells from 3 experiments). BC data in h, and i are the mean ± SEM of
triplicate samples (****P < 0.0001, unpaired two-tailed Student’s t-test). a.u., arbitrary units. Scale bars, 10 μm. Source data are provided as a Source
Data ﬁle
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NPC2, arguing that their transport functions are independently
regulated.
The cholesterol transporting function of LIMP-2 is not entirely
unexpected, considering the cholesterol-binding and fatty acid-
binding and uptake capabilities of the other two members of the SR-
B family, SR-B1 and CD36. It is well established that SR-B1—an
HDL receptor—can selectively transfer HDL-associated cholesterol to
the plasma membrane32. Therefore, we speculate that endocytosed
LDL-associated cholesterol may be handed over to LIMP-2 in a
manner resembling the uptake of HDL cholesterol at the membrane
by the LIMP-2 homolog SR-B1. A scenario seems likely where a
proteolipid complex likely consisting of lysosomal saposins is
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presented to the extended luminal domain of LIMP-2, from where
the lipid enters the tunnel and is translocated to the limiting mem-
brane of the lysosome (Fig. 4f). It is also intriguing to speculate that
similar to the cholesterol transport mediated at the plasma mem-
brane by the LIMP-2 homolog SR-B1 and cytosolic Aster proteins33,
Aster-like proteins or oxysterol-binding protein related proteins
(ORPs) may function downstream of LIMP-2 as cholesterol accep-
tors. The role of LIMP-2 in such a cholesterol transport route may be
of importance for cell types such as Schwann cells. In many other
cells the LIMP-2 cholesterol transport may be rather slow compared
to the more efﬁcient transport by NPC1, but it may contribute to the
variations in the age of disease onset in NPC1 patients. Such varia-
bility might be explained by differences in the way cholesterol is
offered to the transporter, by the abundance of other ligands trans-
ported and/or by differences in the cholesterol derivatives subject to
transfer across the tunnel of the LIMP-2 protein. In this context it is
interesting that glycosylated cholesterol (GlcChol) was found to be
generated by the activity of glycosylceramidase34, whose transport
from the ER to lysosomes depends on the presence of LIMP-214.
In summary, our data support a fundamental physiological role
of LIMP-2 in lipid transport alongside NPC1 and NPC2. Our
results may help direct the development of drugs that can
enhance lipid recycling out of the lysosome and/or alleviate the
negative consequences of lipidoses.
Methods
Materials. BODIPY-cholesteryl linoleate (BC LN) was synthesized as described27.
Human LDL was prepared from pooled plasma of four blood donors from the Finnish
Red Cross (permit 39/2016) by sequential ultracentrifugation35 and labeled with BC
LN27. Lipoprotein-deprived serum (LPDS) was obtained by ultracentrifugation of fetal
bovine serum (FBS) as described35. Oleic acid/BSA complex (8:1) was generated as
previously described36. A431 cells were from ATCC (CRL-1555), HeLa wildtype cells
(ATCC CCL-2), CHO, CHO-M12 cells21, mouse embryonic ﬁbroblasts (MEFs)18 and
the NPC1 knockout CRRISPR HeLa cells37 have been described. Human Silencer Select
LIMP-2 siRNAs (cat# 2652) were from Thermo Scientiﬁc and human NPC1 siRNAs
and control siRNAs against ﬁreﬂy luciferase2; GL2 (both as in ref. 27) from Sigma.
The following mouse LIMP-2 cDNA constructs were used: pmCherry2-N1-
mLIMP-2-mCherry and pmCherry2-N1-mLIMP-2-tunnel mutant (G379W and
V415W)-mCherry.
DiI-LDL (20614ES76), DiI-HDL (20611ES76), and LDL (20613ES05) were
purchased from YEASEN. Alexa Fluor 647 succinimidyl ester (A20106) was
purchased from Life Technologies. Anti-LAMP-2 antibody was purchased from the
Developmental Hybridoma Bank (DSHB, University of Iowa, 1:500). Anti-NPC2
(abcam, ab218192, 1:1000 in 5% skim milk), anti-myc (Cell Signaling, #2276,
1:2000 in 5% skim milk), anti-GFP antibody (sc-9996) was purchased from Santa
Cruz Biotechnology. Anti-mCherry antibody (M11217) was from ThermoFisher.
Anti-actin antibody (M1210-2) and goat anti-mouse IgG HRP (HA1006) were
purchased from HuaAn Biotechnology Co., Ltd.
Cell culture and transfections. Human epithelial carcinoma A431 cells and MEFs
were cultured in DMEM (Lonza), and NPC1-deﬁcient CHO M12 cells in DMEM/
F-12 (1:1, Gibco) supplemented with 10% FBS (Gibco), penicillin/streptomycin
(100 U/ml each, Lonza) and 2 mM L-glutamine (Gibco).
CHO cells were grown in Ham’s F12 medium (Shanghai Basalmedia Technologies
Co., Ltd., L410) supplemented with 10% FBS (Gibco, 10270-106), penicillin 100 UI/ml,
and streptomycin 100 ug/ml at 37 °C in a 5% CO2 incubator.
siRNAs were transfected in A431 cells with HiPerFect (Qiagen) for 72 h and cDNA
constructs with Effectene (Qiagen) for 24 h according to the manufacturer’s
instructions. Transfections of CHO M12 cells were carried with X-tremeGENE HP
DNA transfection reagent (Sigma-Aldrich) for 48 h. Human LIMP-2 plasmids were
transiently transfected using Lipofectamin 3000 transfection reagent (Invitrogen,
100022052) or Polyethylenimine (PEI, Polysciences Inc., 23966-2) using the
manufacturers’ protocols.
Cloning. Human LIMP-2 was cloned into pEGFP-N1 (Clontech) and pmCherry-N1
(Clontech) by PCR-driven overlap extension using 2× Phanta Turbo Master Mix
(Vazyme,P515-01) and ClonExpress II One Step Cloning Kit (Vazyme, C112-02).
hLIMP-2.cmr.GFP, hLIMP-2.cmr.mCherry, and hLIMP-2.cmr.A379W/V415W.
mCherry plasmids were generated with a two-step PCR strategy using overlapping
primers encompassing the desired mutation and the sequence veriﬁed. The N-terminal
His6-tagged luminal domain of hLIMP-2 (aa 35–430) was cloned into PB-T-PAF38
after the protein A tag (protein A-His6-hLIMP-2)39. For the generation of mLIMP-2.
WT.mCherry and mLIMP-2.G379W/V415W.mcherry, the cDNA of mLIMP-WT and
mLIMP-2-G379W/V415W, respectively, were cloned into the vector pmCherry-N1
(Clonetech) by using primers 26 and 27 (see table ‘Primers’) using Phusion polymerase,
10mM DNTPs and 5x HF buffer. Restriction digest of insert and vector with EcoRI and
BamHI was carried out in 2× Y-Tango buffer for 3 h at 37 °C. Subsequently, the vector
was dephosphorylated with FastAP, the samples were separated on a 2% (w/v) agarose
gel and puriﬁed. Ligation was carried out in a 3:1 ratio over night at 24 °C using T4
ligase and buffer. Chemically competent E. coli XL-1 blue were transformed with
1 µl DNA and plated onto LB plates (+Ampicillin). Clones were picked after overnight
incubation at 37 °C, the DNA puriﬁed and the constructs analyzed by Sanger
sequencing (Euroﬁns/ GATC). All enzymes and buffers were from Thermo Fisher.
Primers
Name Sequence
hLIMP-2.A379W.fw GAATAATCCTAAAATGGGCCAAGAGGTTCC
hLIMP-2.A379W.rv GGAACCTCTTGGCCCATTTTAGGATTATTC
hLIMP-2.his6.rv gctgctgtgatgatgatgatgatggctgctgcccatGGGCGCGCCctggaaata
taaattttC
hLIMP-2.his6.fw cagccatcatcatcatcatcacagcagcggc TCCGCGTTTAAACTCG
AGGT
pbtpaf_his_vec.rv gccctggaaatataaattttc
mcherry.fw gcgggcccgggatccatcgccacc
mcherry.rv ggtggcgatggatcccgggcccgc
pmcherry_vec.fw ggtaccgcgggcccgggatcca
pmcherry_vec.rv GCTTGAGCTCGAGATCTGAGTCCGGTAGCGCTAG
LIMP2.456.CD36ct.
pEGFPN1.fw
GTTTGGTTTTTACCTGGCTTTATTGTGCATGCAGAT
LIMP2.456.CD36ct.
pEGFPN1.rv
GATCTGCATGCACAATAAAGCCAGGTAAAAACCAA
AC
For:
26_SCARB2_EcoRI
actGAATTCCatgggcagatg
Rev:
27_SCARB2_BamHI
agtGGATCCGAGGTTCGTATGAG
Recombinant protein expression and puriﬁcation. Recombinant His-tagged
LIMP-2 ectodomain (His6.hLIMP-2(aa35-430)) was expressed in 293 F mamma-
lian cells38 and puriﬁed using standard procedures. The ﬁnal concentration of the
protein solution was 0.4 mg/ml. Saposin A was puriﬁed as previously described23.
SapA was expressed and puriﬁed as described by Popovic et al.23. Brieﬂy, sapA
vector was transformed into Rosetta gami-2(DE3). Cells were grown at 37 °C with
100 mg/ml ampicillin, 34 mg/ml chloramphenicol, 10 mg/ml tetracycline, 50 mg/ml
Fig. 3 LIMP-2-WT but not LIMP-2-G379W/V415W overexpression rescues cholesterol efﬂux from LEs in LIMP-2 deﬁcient cells. a Principle of late
endosomal BODIPY-cholesterol (BC) efﬂux assay in A431 cells. Cells are loaded for 24 h with oleic acid-conjugated BSA to generate lipid droplets (LD). In
parallel, cells are labeled with dextran to visualize late endosomal organelles (LE). Cells are then labeled for 2 h with BODIPY cholesteryl linoleate-labeled
LDL (BC LN-LDL) that enters LE, and chased in serum-free medium to monitor the transfer of BC from LE to LD (labeled with LipidTox during the last 30
min of BC-LN-LDL labeling). b Overlaid confocal images of BC (green), dextran/LIMP-2 (blue), and LipidTox (red) in live A431 cells transfected with the
indicated siRNAs and/or cDNA constructs (LIMP-2-WT or LIMP-2-G379W/V415W overexpressing cells are outlined) at 0 h and 4 h of chase. Scale bar,
10 μm. c Quantiﬁcation of the fraction of BC ﬂuorescence residing in dextran-positive or LIMP-2-positive late endosomes (LE) vs. LipidTox-positive lipid
droplets (LD) after 4 h of chase (n= 21 (siLIMP-2, siCtrl), 22 (siLIMP2+WT.mCherry) or 23 (siNPC1, siLIMP-2+G379W/V415W.mCherry) cells). Data
(mean ± SEM) from 3 experiments, t-test (**P ≤ 0.01, ****P < 0.0001). d Wide-ﬁeld ﬂuorescence micrographs of ﬁlipin stained NPC1-deﬁcient CHO M12
cells overexpressing LIMP-2-G379W/V415W-mCherry. Arrowheads indicate examples of ﬁlipin-positive LIMP-2-containing LEs. Scale bar, 10 μm. For
quantiﬁcation see 1 G. e Analysis of [3H]cholesterol incorporation into cholesteryl esters in LIMP-2-WT and LIMP-2-KO MEFs in the presence and absence
of U18666A or PKF (n= 7 (0 h/5 h), n= 3 (9 h), n= 4 (PKF/U18666A) samples). Data (mean ± SEM) from two (9 h chase) to 3 experiments (5 h chase),
unpaired two-tailed Student’s t-test (*P ≤ 0.05). Source data are provided as a Source Data ﬁle
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streptomycin for 4-6 h and induced with 0.8 mM IPTG overnight at 15 °C and
harvested by centrifugation. The pellet was re-suspended in binding buffer (25 mM
NaCl, 25 mM Tris-HCl, pH 7.0), lysed by sonication, and centrifuged at 15,000 rpm
for 30 min. Then, the supernatant was heated at 90 °C for 15 min. After pelleting
down the precipitate by centrifugation at 15000 rpm for 30 min, the resulting
supernatant was applied directly to a Q-anion-exchange column (GE Healthcare,
17115301) and the bound protein was eluted with a linear gradient of elution buffer
(1M NaCl, 25 mM Tris-HCl, pH 7.0). The peak fractions containing sapA were
collected and further puriﬁed by Superdex-75 size-exclusion column (GE
Healthcare, 29-1487-21) in 50 mM Tris-HCl buffer, pH 7.0. SapA fractions were
concentrated and stored.
Microscale thermophoresis (MST). MST experiments were performed on a
Monolith NT.115 instrument (NanoTemper Technologies). Puriﬁed His-tagged
LIMP-2 protein, labeled using the Monolith His-Tag Labeling Kit Red-tris-NTA
(NanoTemper Technologies) and diluted in buffer with 0.1% Fos-Choline 13 (300
mM NaAc pH 6.0, 150 mM NaCl, 0.05% Tween 20) to a concentration of 25 nM,
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Fig. 4 Regulation of cholesterol homeostasis is altered in LIMP-2 deﬁcient cells. Analysis of LIMP-2 inﬂuence on transcriptional regulation of cholesterol
homeostatic genes. a Termination of SREBP2 processing in response to abundant cholesterol in the ER (induced by LDL loading) is absent or incomplete in
NPC1-silenced and LIMP-2-silenced HeLa cells, respectively. HeLa WT cells were treated with scrambled (ctrl), NPC1 or LIMP-2 siRNA, respectively, and
incubated in either full medium, cholesterol-depleted medium or LDL-loaded medium. The processing of SREBP2 in response to high or low cholesterol
levels was analyzed by immunoblot. b The quantiﬁcation depicts the amount of nSREBP2 after LDL loading in cells treated with scrambled (ctrl), NPC1 or
LIMP-2 siRNA, respectively (n= 3; data (mean ± SEM) from two experiments; *P≤ 0.05, t-test). c Analysis of the effect of cholesterol depletion and re-
addition of LDL cholesterol for 24 h in NPC1-deﬁcient HeLa cells on nSREBP2 formation. Cells were either treated with control siRNA or with LIMP-2
speciﬁc siRNA. The processing of the SREBP2, as well as the expression of the LDL receptor (LDLR) and LIMP-2 was followed by immunoblot. Note that
additional depletion of LIMP-2 led to incomplete termination of nSREBP2 fragment and LDLR formation after cholesterol loading for 24 h. d Quantiﬁcation
of nSREBP2 levels. Nuclear SREBP2 fragment as percentage of total SREBP2 is depicted. (n= 2; data (mean ± SD) from one experiment). e Quantiﬁcation of
LDLR levels after cholesterol loading, normalized to the cholesterol-depleted samples (n= 5; data (mean ± SEM) from two experiments; *P≤ 0.05, **P≤
0.01, unpaired two-tailed Student’s t-test). f Model of the role of LIMP-2 in lysosomal cholesterol efﬂux. Source data are provided as a Source Data ﬁle
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was mixed with cholesterol in binding buffer at indicated concentrations ranging
from 0.1 nM to 6 uM at room temperature. Fluorescence was determined in a
thermal gradient at 60% LED power and medium [low/high] MST power generated
by a Monolith NT.115 from NanoTemper Technologies. Data were analyzed by
MO.Afﬁnity Analysis v2.3.
Membrane protein biotinylation and western blot analysis. The biotinylation
assay was performed using the manufacturer’s protocol (Pierce Cell Surface Protein
Isolation Kit (Thermo Scientiﬁc, 89881)). Brieﬂy, 48 h post transfection, CHO cells
expressing human LIMP-2 constructs were washed twice with cold PBS and
incubated with Sulfo-NHS-SS-Biotin (membrane impermeant) freshly dissolved in
cold PBS for 30 min at 4 °C. After quenching of the unreacted succinimidyl ester
reagent, cells were lysed and the biotinylated proteins were separated using Neu-
trAvidin Agarose beads. The immunoprecipitates were analyzed by Western
blotting using anti-mCherry (M11217; 1:2.000), anti-GFP(sc-9996; 1:500), and
anti-actin (M1210-2; 1:5000) antibodies. β-actin was used to estimate cytosolic
contamination in the biotinylation assay. Uncropped western blots are displayed in
the Source data ﬁle.
DiI-LDL and DiI-HDL binding assay. Twenty-four-hours post transfection, CHO
cells transiently expressing human LIMP-2 plasmids were washed twice with cold
HBSS (Shanghai Basalmedia Technolodies Co. Ltd., B410KJ), pretreated with a
NaAc acidic buffer (0.3 M NaCH3COO pH 4.8, 150 mM NaCl, 1 mMMgCl2, 1 mM
CaCl2) for 2 min, and incubated with 20 μg/ml DiI-HDL or DiI-LDL resuspended
in NaAc acidic buffer for 20 min on ice. Cells were then washed 3 times with NaAc
acidic buffer or HBSS and ﬁxed with 4% paraformaldehyde in PBS for 15 min at
room temperature.
Immunocytochemistry and image analysis. For ﬁlipin staining, cells were ﬁxed
with 4% paraformaldehyde and quenched with 50 mM NH4Cl followed by incu-
bation with 0.05% ﬁlipin (Sigma) in PBS. After washing, the cells were mounted
with Mowiol and imaged with a Nikon Eclipse Ti-E inverted wide ﬁeld microscope
equipped with a Nikon motorized stage and an Andor iXon+ 885 EMCCD camera
with ×40/0.75 NA air objective. The microscope was controlled with NIS-Elements
Advanced Research 4.2 software (Nikon).
Late endosomal ﬁlipin ﬂuorescence in LIMP-2-mCherry-expressing cells was
quantiﬁed by ImageJ. The outlines of LIMP-2-positive and LIMP-2-negative LEs
(within the same cell) were traced manually. After subtracting background ﬂuorescence,
the mean ﬁlipin intensity within individual organelles was measured.
Cells in Fig. 2 and S2, except cells in S2F, were visualized using a Zeiss LSM 800
confocal microscope (Zeiss) equipped with an Airyscan detector, and a ×63 oil
immersion objective (1.4 NA; Zeiss). Images were acquired and processed with
ZEN Blue software (Zeiss). Cells quantiﬁed in Fig. 2i and presented in S2F were
visualized with a Zeiss ×63 1.4 NA oil-immersion lens using a spinning-disk
confocal microscope (Quorum) equipped with a back-thinned EM-CCD camera
(C9100-13, Hamamatsu); images were acquired by and processed with Volocity
software (Perkin-Elmer).
Flow cytometry. To determine binding of AF647-LDL to wild-type and tunnel
mutant LIMP-2 chimera proteins, transiently transfected CHO cells were digested
with accutase (ThermoFisher, A1110501) and washed twice with cold NaAc acidic
buffer (0.3 M NaCH3COO pH 4.8, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2).
Then, cells were incubated with 20 μg/ml AF647-LDL in acidic buffer for 20 min on
ice followed by 3 washes with NaAc acidic buffer and ﬁxed with 2% paraf-
ormaldehyde in PBS. Alexa647-LDL binding was quantiﬁed using the Median
Fluorescence Intensities (MFI) for ligand AF647-LDL for transfected cells from
three different experiments using 10,000 cells. The MFIs were the ones reported by
the ﬂow cytometry software CytoExpert 2.0. Samples were analyzed with a Cyto-
FLEX low cytometer (BECKMAN) and displayed with CytoExpert 2.0 software.
Electron microscopy. For transmission electron microscopy, wildtype and LIMP-
2-deﬁcient mice18 were perfused with 6% glutaraldehyde in phosphate buffer in
accordance with the guidelines of the Institutional Animal Care and Use Com-
mittee at the University of Kiel. We complied with all relevant ethical regulations
for animal testing and research. Tissue blocks were rinsed in phosphate buffer,
postﬁxed in OsO4 for 2 h, and embedded in Araldite or Epon 812 by routine
procedures. Ultrathin sections were collected on Ni-grids, contrasted with uranyl
acetate and lead citrate, and observed with Zeiss EM 900 or EM 902 microscopes.
Live-cell BODIPY cholesterol transport assay. A431 cells, seeded onto glass-
bottom dishes (Nunc LabTek 4-well chambered coverglass), were ﬁrst labeled with
50 μg/ml Alexa Fluor 647-dextran (10,000 MW; Thermo Scientiﬁc) supplemented
with 200 μM oleic acid/BSA in 5% LPDS to label late endosomal organelles and to
induce LDs. The cells were then pulse-labeled for 2 h with 50 μg/ml BC LN-LDL in
serum-free DMEM. During the last 30 min of LDL labeling, HCS LipidTox Red or
HCS LipidTox Deep Red (1:1000; Thermo Scientiﬁc) was added to the medium to
label LDs. The cells were then washed and chased in serum-free CO2-independent
medium (Gibco) for the indicated times and imaged by live-cell confocal
microscopy. Imaging was performed on a Leica TCS SP8 X attached to a motorized
DMi8 inverted microscope with ×63 HC PL APO CS2 water objective (1.20 NA).
Experiments were performed at 37 °C in CO2-independent medium (Gibco) sup-
plemented with HCS LipidTox Red/Deep Red (1:1000) in a fully enclosed
temperature-controlled environmental chamber. Data were acquired with Leica
LAS X (Leica Microsystems). The fraction of BC residing in dextran-positive LEs
and LipidTox-positive LDs was quantiﬁed from background-subtracted images
with ImageJ by using Mander’s overlap coefﬁcient as a measure of colocalization.
[3H]oleic acid incorporation into cholesteryl esters. To analyze cholesterol
esteriﬁcation, MEFs were ﬁrst cultured in 5% LPDS for 72 h, washed with PBS and
labeled with [3H]oleic acid (5 μCi/ml, Perkin Elmer) in serum-free, 2% defatted
BSA (Sigma) medium for 6 h. During labeling, the cells were supplemented with 50
μg/ml LDL, 2 µM U18666A (Sigma) or 2 µM PKF (i.e., Sandoz 58-035, Sigma) as
indicated. The cells were collected by scraping in cold 2% NaCl and lipids were
extracted by the Blight and Dyer method38. Dried lipids were dissolved in
chloroform/methanol (9:1), resolved by TLC using hexane/diethyl ether/acetic acid
(80:20:1) as the mobile phase and visualized by charring. The cholesteryl ester
bands were scraped and radioactivity measured by liquid scintillation counting.
The results were corrected for the volume and procedural losses and plotted against
the total amount of protein in the sample.
[3H]cholesterol esteriﬁcation. [3H]cholesterol LDL complex was prepared using
50 μCi [1,2-3H(N)]-cholesterol (PerkinElmer) to label 1 mg LDL as previously
described (Kanerva et al., 2013). To analyze [3H]-cholesterol incorporation in CEs
by esteriﬁcation, MEFs were cultured in 5% LPDS for 72 h, washed with PBS and
incubated with 50 μg/ml [3H]-cholesterol labeled LDL in serum-free medium for 4
h and chased for another 5 h in serum-free medium. During the labeling, the cells
were supplemented with 2 μM U18666A (Sigma) or 2 µM PKF (Sandoz 58-035,
Sigma) as indicated. The cells were collected and lipids extracted as above. The
cholesterol and cholesteryl ester bands were scraped and radioactivity measured by
liquid scintillation counting.
Click chemistry conjugation of LIMP-2. Fifty-microgram of His-tagged recom-
binant LIMP-2 ectodomain protein was incubated separately with 50 μM of pho-
toclick lipid probes (photoclick trans-sterol (Avanti, 700147p); pacFA (Avanti,
900401p); pacFA ceramide (Avanti, 900404p); and photoclick sphingosine (Avanti,
900600p)) in the dark for 12 h at 4 °C on a rotating shaker. Next, the samples were
exposed to UV light for 15 min (no UV exposure as a negative control) and then
mixed with 20 μM rhodamine-azide (ThermoFisher, T10182), 1 mM Tris(2-car-
boxyethyl)phosphine (TCEP, Sigma-Aldrich), 100 μM Tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl]amine (TBTA, Sigma-Aldrich) and 1 mM CuSO4 in TEV buffer
(10 mM Tris-HCL pH 8.0, 150 mM NaCl, 1 mM EDTA) at room temperature for 1
h. Afterwards, samples were mixed with SDS sample-loading buffer and loaded
without boiling on a 10% SDS-PAGE gel, separated and imaged using a GE
Typhoon Phosphorimager.
Fluorescently labeled lipoproteins. LDL was labeled with Alexa Fluor 647 suc-
cinimidyl ester (ThermoFisher, A20106) according to the manufacturer’s protocol
followed by extensive dialysis using a microdialysis apparatus for small volumes.
Alexa Fluor 647 labeled LDL (AF647-LDL) was next loaded with BODIPY cho-
lesterol (BC) as previously described40. Brieﬂy, BC (Avanti, 810255 P), previously
solubilized in chloroform, was dried under a stream of argon and was subsequently
re-suspended in DMSO. Alexa Fluor 647-labeled LDL was added to the mixture (20
nmol of BC for 1 mg LDL with ﬁnal DMSO concentration of 10%) and this was
further incubated for 2 h at 40 °C, followed by dialysis in PBS containing 1 mM
EDTA using a MWCO 3000 dialysis membrane.
LDL-derived BODIPY-cholesterol transport assay. Giant liposomes were pre-
pared as previously described41. Brieﬂy, liposomes were grown in an Attoﬂuor cell
chamber (Thermo Fisher, A7816) where the coverslip was coated with a thin layer
of low–melting point agarose which was left out to dry overnight. Fifty-microliter
lipid mixture (egg PC (Sigma, 131601C)/cholesterol (Sigma, C8667)/Biotin-PE
(Avanti, 860562P)/Rhodamine-PE (Avanti, 810158P)/Egg SM (Avanti, 860061)/
DGS-NTA(Ni) (Avanti, 790404C) (25/50/22/0.5/1.5/1) (mol%)) was subsequently
soaked up onto the coverslip and dried under argon. Liposomes formed sponta-
neously upon hydration of the dried lipids with NaAc-based acidic buffer (0.3 M
NaCH3COO pH 4.8, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2). Liposomes thus
formed were transferred to a second Attoﬂuor cell chamber (Thermo Fisher,
A7816) in which a coverslip was formerly coated with 7 μg streptavidin in order to
immobilize the biotin-PE-containing liposomes to make them amenable for ima-
ging. Next, 40 μg of puriﬁed ectodomain of the His-tagged LIMP-2 protein was
added to the chamber. After 5 min, Alexa647-labeled LDL lipoprotein was added
and LIMP-2 protein and labeled LDL were allowed to interact for 10-min; incu-
bation was followed by imaging using confocal microscopy. For the BODIPY
cholesterol transport assay, doubly labeled LDL, AF647-LDL(BC), was incubated
with liposomes in the presence or absence of LIMP-2, for 10 min at room tem-
perature. Liposomes were further washed with PBS and visualized by confocal
microscopy.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11425-0
10 NATURE COMMUNICATIONS |         (2019) 10:3521 | https://doi.org/10.1038/s41467-019-11425-0 | www.nature.com/naturecommunications
Preparation of SapA picodiscs. SapA picodiscs were prepared by a variation of a
previously described method23,42. Small unilamellar vesicles (SUVs) were prepared
by mixing BC-cholesterol, bis(monoacylglycero)phosphate (BMP) and egg phos-
phatidylcholine (DOPC, Avanti Polar Lipids) at a ratio of 10:10:80% moles in
chloroform and evaporating the solvent under N2. The dry lipids were dispersed by
vortexing in acidic buffer (50 mM sodium acetate pH 4.8, 150 mM NaCl). The
suspension was subjected to 10 cycles of freezing (with liquid nitrogen) and
thawing followed by sonication in a bath sonicator. SapA was added to a ﬁnal
concentration of 1 mg/mL to solutions of 1 mM liposomes in 50 mM sodium
acetate pH 4.8, 150 mM NaCl. The mixture was incubated at room temperature for
20 min and centrifuged at 21,000 × g to pellet unbound liposomes. The supernatant
containing the SapA picodiscs was stored at 4 °C.
BODIPY cholesterol uptake assay. Twenty-four-hours post transfection, cells
were washed twice with warm HBSS and then pretreated with NaAc-based acidic
buffer (0.3 M NaCH3COO pH 4.8, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2) for
2 min. Then, cells were incubated with of 20 μg/mL BC-containing AlexaFluor647-
labeled LDL or 10 μL of the BC-containing SapA lipoproteins (SapA picodisc
supernatant prepared as described above) at pH 4.8 for 15 min at 37 °C. After-
wards, cells were washed three times with either acidic buffer or HBSS and ﬁxed in
4% paraformaldehyde for 15 min at room temperature.
Molecular modeling and simulations. All-atom molecular models of the LIMP-2
extracellular domain (PDB code: 4F7B, chain A, Neculai et al.15) were constructed
in solution, in the absence of the N-terminal and C-terminal transmembrane
domains or a phospholipid bilayer. Missing side chain heavy atoms were added
using MODELLER 9.1743. Due to the transmembrane domain truncation in this
model, both N-terminal and C-terminal ends of LIMP-2 were modeled as neutral
moieties. Sugar molecules were removed at all glycosylation sites and disulﬁde
bonds were formed between residues [C274, C329] and [C312, C318]. All histidine
sidechains were singly protonated at Nε. The protein was embedded in a solvated
rhombic dodecahedron box consisting of ~150 mM NaCl and ~3 mM cholesterol
for a total of ~62,000 atoms (68 Na+, 50 Cl−, 1 cholesterol, 18580 water mole-
cules). The LIMP-2 cavity was initially devoid of water molecules. The protein,
cholesterol and water molecules were modeled with the CHARMM36 all-atom
force ﬁeld, CGenFF and TIP3P, respectively44,45. Twenty-four initial simulation
states were constructed with a cholesterol molecule positioned manually within 10
Å of the protein with diverse initial orientations, and ﬁfteen initial states were
initiated with different binding poses of cholesterol within the LIMP-2 cavity.
Initial cholesterol binding poses were obtained using AutoDock Vina46 with six
rotatable bonds. Docking was performed with different random seeds in a cubic
area of dimensions 50 × 30 × 40 with grid spacing of 0.375 Å centered within the
cavity. All simulations were performed with GROMACS 4.6.547. All simulations
were conducted at constant temperature (300 K) and pressure (1 atm), using the
Nose-Hoover thermostat48,49 and Parrinello-Rahman barostat50,51, respectively.
Each simulation repeat was independently energy minimized, and subjected to 10
ns of thermalization in the NPT ensemble with protein heavy atoms harmonically
restrained in position with a force constant of 1000 kJ/mol nm2. Covalent bonds
were constrained with SETTLE52 and P-LINCS53 for water and other molecules,
respectively. An integration timestep of 2 fs was used. Simulation repeats were
conducted for 500 ns and 1000 ns for systems initiated with cholesterol in the
solution or docked in the cavity, respectively, for a total of 27 µs of data. Spatial
distribution functions were calculated for each simulation repeat on frames
extracted at an interval of 1 ns, after backbone alignment of each frame to the
LIMP-2 crystallographic structure and removing the initial 50 ns of each repeat.
Cholesterol density was averaged over all frames within a ﬁxed set of overlapping
spheres that approximated the cavity interior. This analysis was performed using
the Visual Molecular Dynamics volmap tool54 for each repeat, and then averaged
over all simulation repeats, weighted by simulation length. Molecular renderings of
LIMP-2 with visualization of the density isosurface was performed using55.
SREBP2 cleavage assays. The assay was adapted from29. HeLa WT and NPC1
KO cells were transfected with the indicated siRNAs (Silencer Select, Thermo
Fisher) for 72 h, then incubated for 16 h in either full medium (DMEM+ 10% FCS
+ 1% Pen-Strep) or cholesterol-depletion medium (DMEM+ 5% LPDS+ 10 µM
mevalonate+ 1 µM atorvastatin (Sigma)), respectively. Then, 50 µg/ml LDL was
added to the respective samples for 2–24 h at 37 °C. 25 µg/ml calpain inhibitor I
(Cayman via Biomol) was added for 1 h at 37 °C before harvesting the cells in PBS
+ complete protease inhibitor cocktail (Roche). Cells were lysed in PBS+ complete
protease inhibitor cocktail containing 0.5% Triton-X 100. The lysates were ana-
lyzed via SDS-PAGE followed by Western blotting and subsequent immunode-
tection using anti-SREBP2 (R&D Systems, MAB7119, 1:250 in 5% skim milk), anti-
LDLR (abcam, ab52818, 1:1000 in 5% skim milk), anti-HMGCR (abcam,
ab1774830, 1:1000 in 5% skim milk), anti-LIMP-2 (self-made, 1:2000 in 5% skim
milk), anti-NPC1 (Novus Biologicals, NB400-148, 1:1000 in 5% skim milk), anti-
GAPDH (Santa Cruz Biotechnology #sc-25778, 1:5000, 5% skim milk) and anti-
Actin (Sigma, A2066, 1:8000 in 5% skim milk) antibodies.
Statistical analysis. Data are expressed as mean ± SEM unless otherwise stated.
For statistical analysis of the SREBP2 assays, an unpaired student’s t-test was
employed. Changes in protein levels were deemed signiﬁcant if the p-value was
<0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the ﬁndings of this study are available from the corresponding
authors upon reasonable request. A reporting summary for this Article is available as a
Supplementary Information ﬁle. The source data underlying Fig. 1c, e, g; 2b, d, h, i; 3c, e;
4a, b, c, d, e; Supplementary Figs. 1A, B, C, D; 2G, H; 3B, C; 4B, C, D, E, F,G, H are
provided as a Source Data ﬁle including also the uncropped and unprocessed scans of
western blots.
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